Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)

Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement AHMEDABAD, India, July 22, 2021 /PRNewswire/ -- Intas Pharm...

Full "IntellAsia: Resources" article